This paper is only available as a PDF. To read, Please Download here.
Abstract
Serial studies were conducted in five women under norgestrel + EE-2 after interrupting
11–34 months of regular use of the medication. A venous blood and an endometrial sample
were simultaneously obtained from each subject between the 22nd and 25th day of the
pseudocycle (last month of contraception) and on the same days of the following three
cycles under no treatment for the measurement of EE-2 content. Values during and after
the first month of no medication were: plasma = 85 ± 6 versus 218 ± 36 (pg/ml; P<0.001) and endometrium = 93 ± 10 versus 29 ± 7 (ng/g wet tissue; P<0.001). A decrement of circulating EE-2 from 346 pg/ml in the first month with no
medication to 14 pg/ml in the third month off the treatment was observed. The EE-2
endometrial uptake of 93 ± 10 (last month of steroidal ingestion) decreased to 29
± 7, 7 ± 2 and 4 ± 0.9 ng/g wet tissue in the following three months of no treatment.
In ![Math Eq]()
instances after interrupting contraception, circulating EE-2 was below the detection
limit of the assay, while endometrial EE-2 uptake was in the range of 3–19 ng/g wet
tissue. These data confirm our apparent controversial report that EE-2 plasma levels
increased during the first month after interrupting medication and support the presence
of the exogenous estrogen in plasma and endometrium after interrupting the steroidal
contraceptive for three months.
instances after interrupting contraception, circulating EE-2 was below the detection
limit of the assay, while endometrial EE-2 uptake was in the range of 3–19 ng/g wet
tissue. These data confirm our apparent controversial report that EE-2 plasma levels
increased during the first month after interrupting medication and support the presence
of the exogenous estrogen in plasma and endometrium after interrupting the steroidal
contraceptive for three months.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ethynyl-estradiol (EE-2) retained in blood and endometrium during and after steroidal contraception.Contraception. 1985; 31: 43-49
- Accumulation of ethynyl-estradiol in blood and endometrium of women under oral contraceptives: The sequential therapy.Fertil. Steril. 1979; 32: 524-527
- Ethynyl-estradiol (EE-2) content in blood and endometrium caused by oral contraceptives.J. Steroid Biochem. 1980; 12: 487-489
- A simultaneous assay to quantitate plasma and endometrium hormone concentrations.Fertil. Steril. 1978; 30: 66-69
- Hormonal content of plasma and endometrium of women taking oral contraceptives.Obstet. Gynecol. 1978; 52: 703-707
- Récepteurs hormonaus. Liaison spécifique del oestradiol á des protéius utérines.C.R. Acad. Sci. Paris. 1967; 265: 354-357
- The metabolism of synthetic estrogens in non-users and users of oral contraceptives.Steroids. 1975; 25: 121-133
- Comparative binding affinity of estrogens and its relation to estrogenic potency.Steroids. 1969; 13: 167-177
- Metabolism in humans of ethynyl steroids.in: Excerpta Med. Int. Congr. Ser.210. 1970: 63
- Effects of some contraceptive steroids on serum proteins of women.Biochem. Pharmacol. 1973; 22: 2277-2281
Article info
Publication history
Accepted:
November 17,
1987
Received:
September 10,
1987
Identification
Copyright
© 1987 Published by Elsevier Inc.
